Hepatic Osteodystrophy: The Mechanism of Bone Loss in Hepatocellular Disease and the Effects of Pamidronate Treatment

Spirlandeli, Adriano L; Dick-de-Paula, Ingrid; Zamarioli, Ariane; Jorgetti, Vanda; Ramalho, Leandra NZ; Nogueira-Barbosa, Marcello H; Volpon, Jose B; Jordão, Alceu A; Cunha, Fernando Q; Fukada, Sandra Y; de Paula, Francisco JA.
Clinics ; 72(4): 231-237, Apr. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-840064

Documentos relacionados

  1. Special Issue: Metabolic Bone Diseases: Molecular Biology, Pathophysiology and Therapy.
  2. Animal Experimental Models in Bone Metabolic Disease.
  3. Fibroblast growth factor 23 and its role in bone diseases.
  4. Targeting type H vessels in bone-related diseases.
  5. Role of peripheral myelin protein 22 in chronic exercise-induced interactions of muscle and bone in mice.
  6. Vasorin as an actor of bone turnover?
  7. Metabolic Health and Disease: A Role of Osteokines?
  8. The Effect of Space Travel on Bone Metabolism: Considerations on Today's Major Challenges and Advances in Pharmacology.
  9. Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation.
  10. Fortified tuna bone powder supplementation increases bone mineral density of lactating rats and their offspring.